{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T05:15:54Z","timestamp":1781327754678,"version":"3.54.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.ejca.2017.07.023","type":"journal-article","created":{"date-parts":[[2017,9,15]],"date-time":"2017-09-15T23:30:20Z","timestamp":1505518220000},"page":"114-121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Isolated limb perfusion for locally advanced angiosarcoma in extremities: A multi-centre study"],"prefix":"10.1016","volume":"85","author":[{"given":"E.A.","family":"Huis in 't Veld","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.J.","family":"Gr\u00fcnhagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Verhoef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.G.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.C.J.","family":"van Akkooi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"van Coevorden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.J.","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.J.","family":"van Houdt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ejca.2017.07.023_bib1","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1245\/s10434-006-9335-y","article-title":"Treatment and outcome of 82 patients with angiosarcoma","volume":"14","author":"Abraham","year":"2007","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2017.07.023_bib2","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1245\/s10434-013-3083-6","article-title":"Cutaneous angiosarcoma: a single-institution experience","volume":"20","author":"Perez","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2017.07.023_bib3","series-title":"Atlas of clinical oncology soft tissue sarcomas","first-page":"99","author":"Pollock","year":"2002"},{"key":"10.1016\/j.ejca.2017.07.023_bib4","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/1097-0142(194805)1:1<64::AID-CNCR2820010105>3.0.CO;2-W","article-title":"Lymphangiosarcoma in postmastectomy lymphedema","volume":"1","author":"Stewart","year":"1949","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2017.07.023_bib5","series-title":"National comprehensive cancer network clinical practice guidelines in oncology: soft tissue sarcoma","author":"[Guideline] NCCN","year":"2017"},{"issue":"7","key":"10.1016\/j.ejca.2017.07.023_bib6","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/jso.23891","article-title":"Neoadjuvant chemotherapy for primary cutaneous\/soft tissue angiosarcoma: determining tumor behavior prior to surgical resection","volume":"111","author":"Oxenberg","year":"2015","journal-title":"J Surg Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2017.07.023_bib7","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ejso.2012.12.018","article-title":"Outcomes of isolated limb perfusion in the treatment of extremity soft tissue sarcoma: a systematic review","volume":"39","author":"Banghu","year":"2013","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2017.07.023_bib8","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1245\/s10434-006-9040-x","article-title":"Isolated limb perfusion with melphalan and tumor necrosis factor alpha for advanced melanoma and soft-tissue sarcoma","volume":"14","author":"Hayes","year":"2007","journal-title":"Ann Surg Oncol"},{"issue":"Suppl. 3","key":"10.1016\/j.ejca.2017.07.023_bib9","doi-asserted-by":"crossref","first-page":"S356","DOI":"10.1245\/s10434-015-4856-x","article-title":"Isolated limb perfusion with melphalan and tumour necrosis factor \u03b1 for in-transit melanoma and soft tissue sarcoma","volume":"22","author":"Smith","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2017.07.023_bib10","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/CMR.0000000000000177","article-title":"Repeated isolated limb perfusion in melanoma patients with recurrent in-transit metastases","volume":"25","author":"Deroose","year":"2015","journal-title":"Melanoma Res"},{"issue":"17","key":"10.1016\/j.ejca.2017.07.023_bib11","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1002\/cncr.29991","article-title":"Role of isolated limb perfusion with recombinant human tumor necrosis factor \u03b1 and melphalan in locally advanced extremity soft tissue sarcoma","volume":"122","author":"Jakob","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2017.07.023_bib12","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/jso.21885","article-title":"TNF dose reduction and shortening of duration of isolated limb perfusion for locally advanced soft tissue sarcoma of the extremities is safe and effective in terms of long-term patient outcome","volume":"103","author":"Hoven-Gondrie","year":"2011","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ejca.2017.07.023_bib13","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ejca.2014.11.020","article-title":"Treatment modifications in tumour necrosis factor-alpha (TNF)\u2013based isolated limb perfusion in patients with advanced extremity soft tissue sarcomas","volume":"51","author":"Deroose","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2017.07.023_bib14","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/jso.23591","article-title":"Oncological outcome of primary non-metastatic soft tissue sarcoma treated by neoadjuvant isolated limb perfusion and tumor resection","volume":"109","author":"Jakob","year":"2014","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ejca.2017.07.023_bib15","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/00000658-199612000-00011","article-title":"Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience","volume":"224","author":"Eggermont","year":"1996","journal-title":"Ann Surg"},{"issue":"2","key":"10.1016\/j.ejca.2017.07.023_bib16","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3109\/02656736.2015.1101170","article-title":"Hyperthermic isolated limb perfusion in locally advanced limb soft tissue sarcoma: a 24-year single-centre experience","volume":"32","author":"Rastrelli","year":"2016","journal-title":"Int J Hyperth"},{"issue":"4","key":"10.1016\/j.ejca.2017.07.023_bib17","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/00000658-195810000-00009","article-title":"Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit","volume":"148","author":"Creech","year":"1958","journal-title":"Ann Surg"},{"issue":"7","key":"10.1016\/j.ejca.2017.07.023_bib18","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S1470-2045(03)01141-0","article-title":"Current uses of isolated limb perfusion in the clinic and a model system for new strategies","volume":"4","author":"Eggermont","year":"2003","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2017.07.023_bib19","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/0277-5379(82)90235-8","article-title":"Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions","volume":"18","author":"Wieberdink","year":"1982","journal-title":"Eur J Cancer Clin Oncol"},{"key":"10.1016\/j.ejca.2017.07.023_bib20","series-title":"WHO handbook for reporting results of cancer treatment","author":"World Health Organisation","year":"1979"},{"issue":"10","key":"10.1016\/j.ejca.2017.07.023_bib21","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1007\/BF02574520","article-title":"Isolated limb perfusion with tumor necrosis factor and melphalan for nonresectable Stewart-Treves lymphangiosarcoma","volume":"9","author":"Lans","year":"2002","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2017.07.023_bib22","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/00130404-200505000-00011","article-title":"A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy","volume":"11","author":"Fury","year":"2005","journal-title":"Cancer J"},{"issue":"8","key":"10.1016\/j.ejca.2017.07.023_bib23","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1245\/s10434-012-2310-x","article-title":"Radiation-associated angiosarcoma after breast cancer: high recurrence rate and poor survival despite surgical treatment with R0 resection","volume":"19","author":"Seinen","year":"2012","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2017.07.023_bib24","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jaad.2005.10.017","article-title":"Angiosarcoma after conservation treatment for breast carcinoma: our experience and a review of the literature","volume":"54","author":"Fodor","year":"2006","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.ejca.2017.07.023_bib25","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.amjsurg.2014.01.007","article-title":"Challenges in the treatment of angiosarcoma: a single institution experience","volume":"208","author":"Singla","year":"2014","journal-title":"Am J Surg"},{"issue":"2","key":"10.1016\/j.ejca.2017.07.023_bib26","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.amjsurg.2010.12.011","article-title":"Surgical management of radiation-induced angiosarcoma after breast conservation therapy","volume":"203","author":"Jallali","year":"2012","journal-title":"Am J Surg"},{"issue":"11","key":"10.1016\/j.ejca.2017.07.023_bib27","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1002\/bjs.7621","article-title":"Long-term outcome of isolated limb perfusion with tumour necrosis factor-\u03b1 for patients with melanoma in-transit metastases","volume":"98","author":"Deroose","year":"2011","journal-title":"Br J Surg"},{"issue":"11","key":"10.1016\/j.ejca.2017.07.023_bib28","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1002\/(SICI)1097-0142(19960601)77:11<2400::AID-CNCR32>3.0.CO;2-Z","article-title":"Angiosarcoma. A report of 67 patients and a review of the literature","volume":"77","author":"Mark","year":"1996","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2017.07.023_bib29","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/annonc\/mdr066","article-title":"Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian Rare Cancer Network","volume":"23","author":"Stacchiotti","year":"2012","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2017.07.023_bib30","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/1346-8138.13558","article-title":"Pazopanib does not bring remarkable improvement in patients with angiosarcoma","volume":"44","author":"Kitamura","year":"2017","journal-title":"J Dermatol"},{"key":"10.1016\/j.ejca.2017.07.023_bib31","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/0360-3016(86)90083-0","article-title":"Impact of improved local control on survival in patients with soft tissue sarcoma","volume":"12","author":"Suit","year":"1986","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.ejca.2017.07.023_bib32","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/cncr.21140","article-title":"Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma","volume":"104","author":"Skubiz","year":"2005","journal-title":"Cancer"},{"issue":"16","key":"10.1016\/j.ejca.2017.07.023_bib33","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1016\/j.ejca.2008.07.037","article-title":"Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group","volume":"44","author":"Schlemmer","year":"2008","journal-title":"Eur J Cancer"},{"issue":"32","key":"10.1016\/j.ejca.2017.07.023_bib34","doi-asserted-by":"crossref","first-page":"5269","DOI":"10.1200\/JCO.2008.17.3146","article-title":"Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study","volume":"26","author":"Penel","year":"2008","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2017.07.023_bib35","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1002\/(SICI)1097-0142(19991115)86:10<2034::AID-CNCR21>3.0.CO;2-P","article-title":"Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face","volume":"86","author":"Fata","year":"1999","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2017.07.023_bib36","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/cncr.22822","article-title":"Docetaxel: a therapeutic option in the treatment of cutaneous angiosarcoma: report of 9 patients","volume":"110","author":"Nagano","year":"2007","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.ejca.2017.07.023_bib37","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s12032-016-0831-z","article-title":"Pazopanib treatment slows progression and stabilizes disease in patients with taxane-resistant cutaneous angiosarcoma","volume":"33","author":"Ogata","year":"2016","journal-title":"Med Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2017.07.023_bib38","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/COC.0b013e3182436ea3","article-title":"Radiation therapy for angiosarcoma: the 35-year University of Florida experience","volume":"36","author":"Scott","year":"2013","journal-title":"Am J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2017.07.023_bib39","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1016\/j.ijrobp.2004.08.008","article-title":"Angiosarcoma of the scalp treated with curative radiotherapy plus recombinant interleukin-2 immunotherapy","volume":"61","author":"Ohguri","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917311437?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917311437?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,27]],"date-time":"2018-08-27T17:06:23Z","timestamp":1535389583000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804917311437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":39,"alternative-id":["S0959804917311437"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2017.07.023","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Isolated limb perfusion for locally advanced angiosarcoma in extremities: A multi-centre study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2017.07.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}